Download Poster (196.18 KB)

Publication
  • WCN •
  • 20 March, 2026 •
  • •

Efficacy of pegcetacoplan in patients with lower baseline proteinuria: A subgroup analysis from the VALIANT trial

Seung Hyeok Han, Hee Gyung Kang, Nicholas Webb, Johan Szamosi, Regina Horneff, Yiwei Zhang, Eli Khankin, Carla M Nester

Available materials

Poster
Publication
  • ERA •
  • 4 June, 2026 •
  • •

Pegcetacoplan population pharmacokinetics and exposure-response analysis in adolescent and adult patients with C3G or primary IC-MPGN

David Kavanagh, Seung Hyeok Han, Larry A Greenbaum, Bradley P Dixon, Ali Keshavarz, Ryan L Crass, Brandon Smith, Xiaoying Yu, Priska Kaufmann

Publication
  • ERA •
  • 4 June, 2026 •
  • •

Safety and low incidence of meningococcal infections with pegcetacoplan in C3G / primary IC-MPGN and PNH

Antonio Mastrangelo, Daniel P Gale, Daniel Zecher, Nabil Melhem, Sanya Norouzi, Bradley P Dixon, Sheena Patel, Liza Alkhori Franzén, Gashu Ayehu, Chauncey Clemons, Régis Peffault de Latour

Publication
  • ERA •
  • 4 June, 2026 •
  • •

Epidemiology of C3G and primary IC-MPGN: a systematic literature review and meta-analysis

Fernando Caravaca-Fontán, Carly Rich, Veruska Carboni, Jameel Nazir, Chris D Poole, Daniel P Gale

Publication
  • ERA •
  • 4 June, 2026 •
  • •

Pegcetacoplan sustained clinical benefit in C3G and primary IC-MPGN through 1 year of therapy: Data from VALIANT/VALE

Fadi Fakhouri, Gema Ariceta, Matthew C Pickering, Moglie Le Quintrec, Marina Vivarelli, Carla M Nester, Bradley P Dixon, Virginia Taliadouros, Johan Szamosi, Kathryn Gordon, Anwesha Mukherjee, Christoph Licht

Sign up for alerts